Imagion BiosystemsIBXXF EV-to-FCF is -1.93 as of Jul. 08, 2026. The stock has 4 warning signs investors should review. Among 98 Medical Diagnostics & Research companies, Imagion Biosystems ranks worse than 1020407.14% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Imagion Biosystems's Enterprise Value is $5.15 Mil.
Imagion Biosystems's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $-2.66 Mil. Therefore, Imagion Biosystems's EV-to-FCF for today is -1.93.
The historical rank and industry rank for Imagion Biosystems's EV-to-FCF or its related term are showing as below:
IBXXF'
s EV-to-FCF Range Over the Past 10 Years
Min: -29.56 Med: -1.08 Max: 1.13
Current: -1.65
During the past 9 years, the highest EV-to-FCF of Imagion Biosystems was 1.13. The lowest was -29.56. And the median was -1.08.
IBXXF's EV-to-FCF is ranked worse than 100% of 98
companies
in the Medical Diagnostics & Research industry
Industry Median: 22.815
vs IBXXF: -1.65
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Imagion Biosystems's PE Ratio (TTM) for today is calculated as:
Imagion Biosystems's share price for today is $0.03.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Imagion Biosystems's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.010.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Imagion Biosystems EV-to-FCF Related Terms
Imagion Biosystems EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Imagion Biosystems's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Imagion Biosystems's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Imagion Biosystems EV-to-FCF vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Imagion Biosystems's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Imagion Biosystems's EV-to-FCF falls into.
Imagion Biosystems's current Enterprise Value is $5.15 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Imagion Biosystems's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $-2.66 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Imagion Biosystems (IBXXF) has a EV-to-FCF of -1.93 as of Jul. 08, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Imagion Biosystems and its competitors. According to the industry distribution chart, Imagion Biosystems ranks #999999 out of 98 companies in the Medical Diagnostics & Research industry.
Is Imagion Biosystems' EV-to-FCF too high?
Imagion Biosystems' current EV-to-FCF is -1.93. Based on the distribution chart, Imagion Biosystems ranks #999999 out of 98 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does Imagion Biosystems' EV-to-FCF compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Imagion Biosystems ranks #999999 out of 98 companies for EV-to-FCF. This places Imagion Biosystems in the lower half of its industry. The industry median EV-to-FCF is 22.82. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Diagnostics & Research company?
The median EV-to-FCF among Medical Diagnostics & Research companies is 22.82, based on 98 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Imagion Biosystems and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-FCF is 22.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Imagion Biosystems's current EV-to-FCF is -1.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Imagion Biosystems stock overvalued right now?
Based on GuruFocus' analysis, Imagion Biosystems (IBXXF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.11, compared to a current price of $0.03 — trading 72.7% below its estimated fair value. The current EV-to-FCF is -1.93. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Imagion Biosystems (IBXXF), the current EV-to-FCF is -1.93 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Imagion Biosystems Ltd operates in the field of non-invasive detection of specific solid tumor cancers by use of magnetic nanoparticles. Its principal continuing activities consisted of Nanotechnology; Biotechnology; Cancer Diagnostics; and Medical Imaging using Magnetic Resonance and Superparamagnetic Relaxometry. The company only operating segment - Research and Development. Its principal business activities consist of nanotechnology, biotechnology, cancer diagnostics, and medical imaging using Superparamagnetic Relaxometry. In addition, the company is engaged in the research and development of its clinical phase lead product which is intended for the detection and staging of metastatic HER2 breast cancer. The company operates in Australia and the USA, with revenue from Australia.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IBXXF has been successfully added to your 